Kornimate/medical-research-clean huggingface dataset:
management and outcome of mesh infection after abdominoplasty in a tertiary care centre

Conditions: Abdominal Infection

Summary: hernia repair is among most frequent surgical interventions. the use of abdominal mesh in hernia repair has become the gold standard strategy, reducing the risk of relapse. the mesh infection risk is estimated lower than 1% in simple situations, but can increase up to 20% in complicated patients. risk factors are well known, but we lack data regarding the therapeutic strategies and outcomes. this study aims to describe the characteristics and management of abdominal mesh infections, and the related outcomes.


Eligibility criteria:
inclusion criteria: * parietal mesh infection * age \> 18 exclusion criteria: * non french speaking patients. * persons under tutorship or curatorship.

Keywords: mesh infection abdominoplasty
a single bolus of dexmedetomidine versus nalbuphine in postoperative agitation

Conditions: Cleft Palate

Summary: the hypothesis of this study is to investigate and compare the efficacy between the administrations of single intravenous (iv) dose of dexmedetomidine versus nalbuphine in preventing immediate postoperative agitation in children undergoing cleft palate repair.

a written informed consent will be taken from the guardian of children.patients will be assigned randomly to three groups (30 subjects each) to be anesthetized. the study drug will be delivered in opaque bags labeled "study drug" and 90 patients will be allocated in three groups (of 30 patients each) to receive the study drug at the end of surgery; a single dose of 0.5 µ/kg iv dexmedetomidine (group d) or a single dose of 0.1 mg/kg iv nalbuphine (group n) or same volume of saline placebo (group c).

Eligibility criteria:
inclusion criteria: * children (age 1-7 years) of american society of anaesthesiologists physical status (asa) i-ii * elective cleft palate repair ± cleft lip surgery under general anesthesia. exclusion criteria: * ventriculo-peritoneal shunt * suspected meningitis * congenital hydrocephalus * clinical signs of suspected increased intracranial pressure * on treatment for seizures or metabolic diseases * children with developmental delay * hypersensitivity to dexmedetomidine or nalbuphine
lifestyle modification for type 2 diabetes involving reduction of after-meal blood glucose elevations

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to determine if a lifestyle modification program (gem) that focuses on reducing after-meal blood glucose elevations can improve blood glucose control in people with type 2 diabetes. half of the participants will continue their routine medical care, and half will receive five sessions of gem in addition to their routine care. the two groups will be assessed using diabetes-relevant medical, behavioral and psychological measures.


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes within the past 5 years * age \>24 and \<80 years * hba1c \>7.0% * approval of primary care physician to participate exclusion criteria: * currently using, or used within the last 3 months, medications that directly lower bg (e.g., insulin, sulfonylureas, glinides, or dpp-4 inhibitors). * currently using, or used within the last 3 months, thiazides at doses above hctz 25 mg or equivalent, or loop diuretics above furosemide 20mg or equivalent. * currently pregnant or contemplating pregnancy in the coming year * currently using, or used within the last 3 months, medications that impede weight loss (e.g., prednisone) * having conditions that preclude increasing physical activity, e.g. severe neuropathy, active cardiovascular disease, emphysema, osteoarthritis, stroke. * undergoing cancer treatment * history of lactic acidosis * diagnosed with renal impairment
a study of cg-806 in patients with relapsed or refractory aml or higher-risk mds

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes

Summary: this study is being done to evaluate the safety, tolerability and antitumor activity of oral cg-806 (luxeptinib) for the treatment of patients with acute myeloid leukemia (except apml), secondary aml, therapy-related aml, or higher-risk mds, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.

this is a multicenter, open-label, phase 1 a/b dose escalation study of safety, pharmacodynamics, and pharmacokinetics of cg-806 in ascending cohorts (3+3 design) to determine the mtd or recommended dose in patients with relapsed or refractory acute myeloid leukemia (except apml), secondary aml, therapy-related aml, or higher-risk mds whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation. this is to be followed by a cohort expansion phase.

Eligibility criteria:
key inclusion criteria: * age ≥18 years * life expectancy of at least 3 months * ecog performance status ≤ 2 * patients must be able to swallow capsules * adequate hematologic parameters, unless cytopenias are disease caused * adequate renal, liver and cardiac functions key exclusion criteria: * patients with gvhd requiring systemic immunosuppressive therapy * uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinically significant disease related metabolic disorder * clinically significant leukostasis * treatment with other investigational drugs or receipt of cytotoxic therapy within 14 days prior to first study treatment administration * receipt of cellular immunotherapeutic agents within 4 weeks prior to first study treatment administration

Keywords: cg-806 aptose flt3 flt3-itd d835y f691l btk c481s tp53 nras idh1 bcl2 gilteritinib quizartinib midostaurin crenolanib venetoclax ibrutinib acalabrutinib zanubrutinib loxo-305 arq 531 aml acute myeloid leukemia mds myelodysplastic syndrome cll chronic lymphocytic leukemia resistant refractory relapsed intolerant kinase inhibitor non covalent luxeptinib
a study in healthy volunteers and patients with chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: this two-part, phase 1 protocol will be the first clinical study of abi-h0731. part i will be a phase 1a dose-ranging assessment of abi-h0731 in healthy adult volunteers. if the dose-related safety, tolerability and pharmacokinetics (pk) of abi-h0731 in human volunteers are deemed satisfactory, then the study will advance to part ii, a phase 1b dose-ranging assessment of abi-h0731 in non-cirrhotic, chb patients.


Eligibility criteria:
healthy volunteers: 1. male or female between 18 and 65 years old with a bmi of 18-32kg/m2 2. must be in good health and not have any health condition which could interfere with the absorption, distribution or elimination of study drug, or with the clinical and laboratory assessments in this study chb patients: 1. male or female between 18 and 65 years of age, with a bmi of 18-35kg/m2 and a minimum body weight of 45 kg 2. must have chronic hepatitis b with no history of clinical decompensation 3. seropositive for hiv, hcv, or hdv antibody at screen 4. previous treatment with any hbv antiviral treatments within the last 3 months 5. other known cause of liver disease, including nash
rituximab desensitization therapy for patients on the waiting list for kidney transplant

Conditions: End Stage Renal Disease

Summary: this is a study of patients who have a high risk of kidney rejection before kidney transplant. the hypothesis is that treatment with a medication called rituximab will make it possible for them to receive a kidney transplant from a donor who previously did not present a good match.


Eligibility criteria:
inclusion criteria: * active status on a kidney transplant waiting list with positive cross match against a living donor exclusion criteria: * receipt of a live vaccine within 4 weeks prior to randomization * previous treatment with rituximab

Keywords: transplant desensitization kidney transplant
clinical evaluation of nanoionomer filling in primary teeth

Conditions: Dental Caries

Summary: this clinical trial was performed to evaluate the nano-filled resin modified glass ionomer (rmgi) -with a brand name of "ketac nano"- as a filling material for the treatment of caries in primary teeth. children aged 5-8 years were selected and treated with either ketac nano or another conventional rmgi called vitremer. then, the treated children were evaluated at baseline, after one yeat and after two years. the hypothesis to be tested in the present study was: the clinical performance of nano-filled rmgi (ketac nano) in class i primary molars will differ from that of its preceding conventional rmgi (vitremer).

first, shear bond strength of each material to primary molars dentin specimens were measured (n=10) using a notched-edge crosshead. independent sample t-test was used for statistical analysis. then, a split mouth designed clinical trial was performed in which nano-filled rmgi; ketac nano (kn) and conventional rmgi; vitremer (vr) were used to restore class i cavities of primary molars. each material group (n=30) was evaluated according to the modified united states public health service (usphs) regarding marginal discoloration, marginal adaptation, color match, anatomic form and recurrent caries, at baseline, after one year and after two years. wilcoxon signed- rank test and chi-square test were used for statistical analysis.

Eligibility criteria:
inclusion criteria: * the presence of a bilateral identical pair of primary molars in the same arch containing initial occlusal caries (a minimum of two pits or fissures without any cusp destruction). exclusion criteria: * handicapped or uncooperative children and children with extensive or rampant caries.

Keywords: nano-filled resin modified glass ionomer clinical performance class i primary teeth dentin bond strength filling of class i
a trial of hydrus microstent versus goniotomy

Conditions: Glaucoma; Glaucoma, Open-Angle

Summary: the goal of this clinical trial is to evaluate the comparative efficacy and safety of hydrus microstent, incisional goniotomy, and excisional goniotomy when combined with cataract surgery in patients with mild and moderate open-angle glaucoma. the main questions it aims to answer are: * how do the intraocular pressure lowering effects of these three microinvasive glaucoma surgeries compare? * how do the safety profiles of these three microinvasive glaucoma surgeries compare? participants will be randomized to one of these three microinvasive glaucoma surgeries in combination with cataract surgery.


Eligibility criteria:
inclusion criteria: * visually significant cataract planned for surgery * mild to moderate open-angle glaucoma, including pigmentary glaucoma and pseudoexfoliation glaucoma * mild stage glaucoma includes glaucomatous optic neuropathy and visual field mean deviation better than -6.0 db, with no points in the central 5 degrees \<15 db * moderate stage glaucoma includes: 1) glaucomatous optic neuropathy and visual field mean deviation equal to or worse than -6.0 db but no worse than -12.0 db and no central 5 degree points \<15 db or 2) mean deviation -12.0 db or better with 1 central 5 degree point \<15 db * medicated iop between 10 to 31 mm hg, inclusive, at time of decision for surgery * willing and able to understand and provide informed consent * willing and able to attend postoperative examinations per protocol schedule exclusion criteria: * prior argon laser trabeculoplasty, laser peripheral iridotomy, incisional glaucoma surgery, or cyclophotocoagulation * selective laser trabeculoplasty within 90 days of study enrollment * iridotrabecular contact for 180 degrees or greater * peripheral anterior synechiae in nasal or inferior angle * best corrected visual acuity worse than 20/200 * phacodonesis on pre-operative examination * vitreous in anterior chamber on pre-operative examination * nanophthalmos * anti-platelet and anticoagulant medications other than aspirin 81mg daily * active treatment for another ophthalmic condition in either eye (e.g., anti-vegf injections, steroids for corneal transplant) * abnormality in study eye that could affect tonometry * glaucoma diagnosis other than the above * normal tension glaucoma * conditions that can cause elevated episcleral venous pressure (e.g., sturge-weber syndrome, graves disease, retrobulbar tumor) * history of uveitis in either eye * inability to complete gonioscopy examination * use of oral steroids within 90 days or anticipated use of oral steroids * oral medications that can affect iop, including oral carbonic anhydrase inhibitors such as acetazolamide and methazolamide * history of steroid-associated iop elevation * medically unfit for attending planned study visits * involvement in another interventional research study

Keywords: incisional goniotomy excisional goniotomy hydrus microstent goniotomy
effect of green tea on treatment of lupus

Conditions: Autoimmune; Lupus Erythematosus, Systemic

Summary: this randomized double blind clinical trial performed on 68 patients (32 in intervention and 36 in control group) diagnosed with sle. the patients in intervention group were given daily dose of 1000mg of aqueous green tea extract (of 6 gram of dried green tea leaf) in form of two capsules ( 500 mg). also in control group, the patients were given daily dose of 1000mg of cellulose in form of two capsules ( 500 mg) variables include sle disease activity, some biomarkers of inflammation and oxidative stress and anthropometric indicators at baseline and end of the study. the investigators used sledai (systemic lupus erythematous disease activity index ) questionnaire for evaluating the clinical signs of the disease. the questionnaires filled out at baseline and after 3 month.

noting

Eligibility criteria:
inclusion criteria: the patients older than 15 years,diagnosed with systemic lupus erythematous (sle) according to acr(american college of rheumatology) criteria. exclusion criteria: * patients with other autoimmune diseases (diabetes, ...) * cardiovascular disease * patients with infectious or liver disease; * severe infection * pregnancy * breastfeeding * smoking * alcohol consumption * use of any dietary supplements * changing of medication during the study period

Keywords: disease activity
effects of ambient air pollution exposure in patients with stable angina pectoris during normal daily activities

Conditions: Angina Pectoris; Coronary Heart Disease

Summary: the purpose of this study is to identify whether exposure to ambient levels of air pollution during normal daily activities has a functional impact on patients with coronary heart disease

exposure to air pollution has been shown in epidemiological studies to be closely linked to cardiovascular morbidity and mortality. the exact components of air pollution that underlie the cardiovascular effects are not yet known, but combustion-derived particulate matter is suspected to be the major cause. in controlled exposure studies, we have recently demonstrated that exposure to diesel exhaust causes increased myocardial ischaemia with exercise in patients with asymptomatic coronary artery disease. the mechanism behind this effect is not yet understood, but we have shown that diesel exhaust exposure causes an acute impairment of two important and highly relevant aspects of vascular tone: vasomotor tone and endogenous fibrinolysis. in this study we propose to investigate the effects of exposure to ambient levels of air pollution on patients with stable, symptomatic angina pectoris, during their daily lives.

Eligibility criteria:
inclusion criteria: * documented coronary artery disease * symptoms of stable angina pectoris * positive bruce exercise stress test between 3 and 13 minutes exclusion criteria: * history of arrhythmia * severe 3 vessel coronary disease or left main stem stenosis that has not been revascularised * resting conduction abnormality * digoxin therapy * uncontrolled hypertension * renal or hepatic failure * unstable symptoms or acute coronary syndrome within 3 months

Keywords: angina pectoris exercise capacity myocardial ischaemia air pollution
covid-19 project echo in nursing homes

Conditions: Covid19

Summary: nursing homes are ground zero for the covid-19 pandemic. nursing homes are ill-equipped for the pandemic; though facilities are required to have infection control staff, only 3% have taken a basic infection control course. significant research has focused on infection control in the acute care setting. however, little is known about the implementation of practices and effective interventions in long-term care facilities.the investigators propose an intervention utilizing project echo, an evidence-based telehealth model, to connect penn state university experts with remote nursing home staff and administrators to proactively support evidence-based infection control guideline implementation. our study seeks to answer the critical research question of how evidence-based infection control guidelines can be implemented effectively in nursing homes

the investigators will recruit 200 nursing homes with approximately 24,560 residents from across the united states through collaborations with our stakeholders. nursing homes will be randomized to one of two arms: 1) ahrq-funded covid-19 echo that includes 16 weekly telehealth sessions addressing covid-19 guidelines and best practices or 2) ahrq-funded covid-19 echo plus an additional 9 sessions with a focus on cdc infection control training. randomization will be stratified by characteristics of nursing homes to ensure balance among the two trial groups, including size (number of beds),geographic location, and current covid-19 infection rate. patient-centered outcomes (nursing home residents with covid-19 infections, hospitalizations, deaths, and qol) will be assessed at baseline, 4, 6, 12, and 18 months. our study is guided by the re-aim framework to critically evaluate both effectiveness and implementation outcomes of the proposed intervention. the re-aim framework is frequently utilized to improve sustainable adoption and implementation of effective, generalizable, evidence-based interventions like project echo.

Eligibility criteria:
inclusion criteria for facilities skilled nursing facility in united states access to computer or electronic device exclusion criteria for facilities previously participated in project echo covid-19 series either through penn state or another institution

Keywords: project echo telehealth
an observational study of dual and triple therapies based on pegasys (peginterferon alfa-2a) in patients with chronic hepatitis c

Conditions: Hepatitis C, Chronic

Summary: this multi-center, observational study will evaluate the efficacy and safety of dual and triple therapies based on pegasys (peginterferon alfa-2a) in patients with chronic hepatitis c. patients receiving treatment with either pegasys plus ribavirin or pegasys plus ribavirin plus telaprevir/boceprevir will be observed for the duration of their treatment and for up to 24 weeks of follow-up.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * chronic hepatitis c (all genotypes, naïve or treatment experienced, hcv mono-infected or hcv-hiv co-infected) * receiving either dual therapy (pegasys plus ribavirin) or triple therapy (pegasys plus ribavirin plus telaprevir/boceprevir) * no contra-indications to pegasys and ribavirin therapy or to treatment regimen containing protease inhibitor (telaprevir or boceprevir) as detailed in local prescribing information * quantitative serum hcv rna by pcr test before initiation of treatment exclusion criteria: * hepatitis a/b co-infection * evidence of severe illness, active malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study * pregnant or breast-feeding women
innovative physical therapy modalities in people with a neurological disease: oculomotor therapy and adapted yoga

Conditions: Nervous System Diseases; Oculomotor; Disorder; Physical Dependence; Physical Inactivity; Treatment Adherence

Summary: physiotherapy is a discipline which englobe not only the rehabilitation of physical pathologies but also their prevention. that is why this study pretends to upgrade this part of the physical therapy specialty while prove new therapies using innovation technologies in people with any physical neurological disease. the main problem that this study pretends to solve is the necessity of develop new activities to improve quality of life and integration in people with any physical neurological disease. people with any neurological disease used to present visual problems, pain, fatigue, functional dependence, and a bad quality of life and it appears that exercise habits could improve all these deficiencies. however, how could people with any physical neurological disease participate in an integrated way in nowadays physical activities? the main objective of this study is to prove the effectiveness on visual acuity, quality of life, pain decreasing, functional independence and fatigue of physical therapy modalities in people with any physical neurological disease. the experiment will take part with 128 participants, divided equally in control and experimental groups. both are going to receive adapted yoga sessions but only experiment group is going to test oculomotor therapy. descriptive investigation would take part at the end of the intervention to analyze all results.

participants will complete several questionnaires at the start and at the end of the study, to quantify the progress. also, a professional will evaluate the sessions. sessions are going to be online and offline, and both will be recorded (with the registered permission of the participants), so they could be analyzed lately.

Eligibility criteria:
inclusion criteria: * users equal or over 18 years old. * to have already signed all the obligatory documents. * to have a physical neurological disease. * to have an electronic with internet connection. * to collaborate on the correct develop of the project. exclusion criteria: * serious cognitive or physical damage. * doctor disapproval. * be unable to understand the indications. * be unable to read.

Keywords: physical therapy modalities muscular stretching therapy oculomotor therapy adapted yoga technologies